New drugs to boost graft-versus-host disease treatment market by 2018

The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a compound annual growth rate (CAGR) of 6.59%.

According to the latest report from research and consulting firm GlobalData, this growth, which will occur over six major markets (6MM: the USA, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period.

Eirini Vavatsikou, GlobalData’s an analyst covering Immunology, says: “Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics (Nasdaq: OSIR) and Mesoblast’s (ASX: MSB) first-to-market Prochymal [remestemcel-L] expected to generate sales of $12.2 million in 2018. Dr Falk Pharma’s Budenofalk [budesonide] is forecast to enter the European GVHD market in 2016, while ATG-Fresenius (ATG-F) will arrive in the US market in 2017. These two products are estimated to achieve 2018 sales of $11,900 and $8 million, respectively.”